Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMA401 in Postherpetic Neuralgia
NCT02426411Phase 2Withdrawn
- Sponsor
- Spinifex Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of olodanrigan in postherpetic neuralgia (PHN), sponsored by Spinifex Pharmaceuticals. Planned start Jun 2015; status: withdrawn.
02
Drugs
olodanrigan
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT02426411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426411.